HUTCHMED (China) (HCM) Bank of America 2025 Healthcare Conference summary

Commercial and market expansion

• Uptake in the U.S. is increasing, driven by expanded insurance coverage and strong efficacy and safety profile in late-line settings.

• Japan shows strong quarter-over-quarter growth post-insurance coverage, with a 78% increase and $10.5 million in recent quarterly revenue.

• EU growth is expected to accelerate as more countries secure insurance coverage and formulary listings.

• Broader market capture strategies are being implemented to enhance penetration.

Competitive landscape and product development

• Ongoing investigator-initiated trials and combination studies in China are expanding data for fruquintinib, supporting future growth.

• Recent competitor data in third-line plus settings is shaping the evolving market opportunity.

Clinical trial updates and regulatory progress

• SAVANNAH trial for sovleplenib showed a 55% ORR and 7.5 months PFS in MET-amplified/overexpressed patients; global submission awaits SAFFRON phase III results.

• SACHI phase III trial in China demonstrated positive results in EGFR-resistant populations, with data to be presented at ASCO.

• SANOVO phase III trial targets frontline MET-overexpressed patients, aiming to demonstrate value over single-agent therapy.